2024 Women’s Cardiometabolic Health and Wellness Masterclass
ACTIVITY TITLE
2024 Women’s Cardiometabolic Health and Wellness Masterclass
ACTIVITY DATE
April 18-20, 2024 at the Laguna Cliffs Marriott Resort, Dana Point, CA
EDUCATIONAL GRANT SUPPORT
The 2024 Women’s Cardiometabolic Health and Wellness Masterclass is supported in part by an educational grant from Esperion Therapeutics, Inc.
TARGET AUDIENCE
The educational design of this activity addresses the needs of US-based healthcare professionals, including endocrinologists, cardiologists, internists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, and physician assistants.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Recognize the symptoms and clinical presentation of acute and chronic cardiovascular diseases in women, including heart failure, valvular disease, and acute coronary syndromes
- Discuss the relationship between conventional and women-specific cardiometabolic risk factors, as well as their impact on the development of cardiometabolic diseases in women across the lifespan, including diabetes, dyslipidemia, hypertension, obesity, kidney disease, and cardiovascular disease
- Evaluate the connection between mental health, cognitive decline and cardiometabolic well-being in women.
- Review how key targets in the inflammatory pathway contribute to the development and progression of cardiovascular disease
- Summarize recent evidence for emerging therapies in cardio-renal-metabolic medicine in order to stay current with the most recent updates, including women-specific considerations
- Select individualized and evidence-based approaches for the management of women with cardio-renal-metabolic risk, including the optimization of CVD prevention, obesity, hypertension, dyslipidemia, kidney disease, MASH and type 2 diabetes.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this live activity for a maximum of 10.75 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 10.75 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 10.75 contact hour(s) (1.075 CEUS) of the Accreditation Council for Pharmacy Education.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is a registration fee for participating and receiving CME/CE credit for this educational activity. Registration information can be found here.
HOW TO REQUEST CE CREDIT
Learners may earn up to a maximum of 12.5 AMA/ACPE/ANCC credits for attending all General Sessions (earn up to 10.75 hours) and CME Supported Sessions (earn up to 1.75 hours). Full instructions for how to claim credit can be found on the mobile app.
DISCLOSURES
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Information on faculty disclosures will be posted before the meeting.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
